INDIANAPOLIS (AP) — Eli Lilly says it’s changed the outcome goals for a late-stage patient study of its closely watched experimental drug for Alzheimer’s disease, solanezumab.
The Expedition3 trial had two primary outcome measures: changes in participants’ cognition and their daily function. Now cognition will remain a primary outcome measure, while function will be a secondary measure of the drug’s effectiveness.
Eli Lilly and Co., based in Indianapolis, said in a statement Tuesday it made the change because “emerging scientific evidence supports the idea that cognitive decline precedes and predicts functional decline” in Alzheimer’s patients.
Late-stage studies usually are the last ones before drug developers seek regulatory approval. Investors, apparently nervous about the news after several similar drugs have failed in testing, drove shares down $2.67, or 3.6 percent, to $71.24.
Copyright Associated Press